欧盟批准了Alvotech的denosumab生物类似药用于治疗骨质疏松症和与癌症相关的骨问题,从而提高治疗准入率并降低成本. The EU approved Alvotech’s denosumab biosimilar for osteoporosis and cancer-related bone issues, boosting treatment access and lowering costs.

欧盟委员会已经批准了Alvotech的生物类同AVT03, 这是一种代诺苏马布替代物,用于治疗欧洲、瑞士和联合王国各地高级癌症患者的骨质疏松症和预防骨质并发症。 The European Commission has approved Alvotech’s biosimilar AVT03, a denosumab alternative, for treating osteoporosis and preventing bone complications in advanced cancer patients across the EEA, Switzerland, and the UK. AVT03将由STADA和Reddy博士在Kefdensisé、Zvograí、Acvybraí和Xbonzyí品牌下销售。 Approved based on extensive data confirming safety and efficacy, AVT03 will be marketed by STADA and Dr. Reddy’s under the brands Kefdensis®, Zvogra®, Acvybra®, and Xbonzy®. 该举措旨在扩大获得关键治疗的机会,并支持保健成本的可持续性。 The move aims to expand access to critical treatments and support healthcare cost sustainability.